Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Kiniksa Pharmaceuticals

NASDAQ KNSA
$35.71 0.20 0.56%
Today share price
Bermuda
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 28.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
1.69B
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
1.54B
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.35
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
76.15M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
80.54 %

Upcoming events Kiniksa Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Kiniksa Pharmaceuticals

Stock analysis Kiniksa Pharmaceuticals

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-99.78 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
3.22 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-324.33 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
32.69 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-3.71 -50.00

Price change Kiniksa Pharmaceuticals per year

18.17$ 35.71$
Min Max

Summary analysis Kiniksa Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Kiniksa Pharmaceuticals

Revenue and net income Kiniksa Pharmaceuticals

All parameters

About company Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Address:
Clarendon House, Hamilton, Bermuda, HM 11
Company name: Kiniksa Pharmaceuticals
Issuer ticker: KNSA
ISIN: BMG5269C1010
Country: Bermuda
Exchange: NASDAQ
Currency: $
IPO date: 2018-05-24
Sector: Healthcare
Industry: Biotechnology
Site: https://www.kiniksa.com